Merck Frosst Canada Ltd.
Tama Donoahue-Walker, Director, Corporate Affairs (Ontario)
T 416.368.3308
F 416.368.9118
E tama_donoahue-walker@merck.com
W www.merckfrosst.com
At Merck Frosst, patients come first. Merck Frosst Canada Ltd. is a research-driven pharmaceutical company. Merck Frosst discovers, develops, manufactures and markets a broad range of innovative medicines to improve human health. The Merck Frosst Centre for Therapeutic Research, one of the largest biomedical research facilities in Canada, has the mandate to discover new therapies for the treatment of respiratory diseases, inflammatory diseases, diabetes and osteoporosis. Merck Frosst is one of the top 20 R&D investors in Canada, with an investment of $117 million in 2004. The Company is committed to fostering partnerships to deliver the most valuable health outcomes for Canadian patients.
Merck Frosst is a recognized leader in the treatment of asthma, osteoporosis, HIV/AIDS, glaucoma, prostate disease, migraines and infectious diseases. The Company also markets an extensive line of cardiovascular products for high blood pressure, elevated cholesterol and heart failure as well as a broad range of vaccines. Based in Montréal, Quebec, Merck Frosst employs nearly 1,900 people including more than 300 of the world’s leading scientific personnel. It is also firmly committed to science education and sponsors a number of programs designed to spark young people’s interest in science.
BROWSE TENANTS
- AIM Therapeutics Inc.
- Ambit Biosciences
- ApoPharma Inc.
- ArcticDx Inc.
- AstraZeneca Canada Inc.
- Axela Inc.
- AXS Biomedical Animation Studio
- BioDiscovery Toronto
- BioFinance Canada
- BioQuest Innovations Inc.
- Biosign Technologies Inc.
- BML Canada Limited
- Canadian Biotechnology Education Resource Centre (CBERC)
- Cascade Therapeutics Inc.
- Cassandra Capital L.P.
- Celtic House Venture Partners
- Clera Inc.
- Constab International Inc.
- Critical Outcome Technologies Inc.
- CVCA - Canada’s Venture Capital & Private Equity Association
- Diagnostic Systems Laboratories
- GlaxoSmithKline Inc.
- htx.ca - The Health Technology Exchange
- Heenan Blaikie LLP
- The Innovations Group, University of Toronto
- iLOOKABOUT Inc.
- Innovation Institute of Ontario
- Interface Biologics
- InVisage Technologies
- In Vitro Drug Safety & BioTechnology
- Kanata Chemical Technologies
- Larial Proteomics
- MaRS Landing
- The Martin Prosperity Institute
- McLaughlin Centre for Molecular Medicine
- McLaughlin-Rotman Centre for Global Health - Program on Life Sciences, Ethics and Policy
- Merck Frosst Canada Ltd.
- NeurAxon Inc.
- NPS Pharmaceuticals
- Ontario Cancer Biomarker Network (OCBN)
- Octopz Inc.
- Ogilvy Renault LLP
- Ontario Institute for Cancer Research
- Ontario Geonomics Institute
- Ontario Innovation Trust
- Ontario Society for Excellence in Techology Transfer
- Ozmosis Research
- PricewaterhouseCoopers LLP
- RBC Royal Bank
- RBC Venture Partners
- Receptor Therapeutics Inc.
- Sigma Analysis & Management Ltd.
- Skymeter Corporation
- The Biotechnology Initiative
- Toronto Region Research Alliance
- Transition Therapeutics
- University Hospital Network Technology Development & Commercialization Office
- University Health Network
- University of Toronto Asset Management Corporation
- University of Waterloo
- Vasogen
- YYZ/Blue Sky Capital Corporation